Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ)

3.6400 +0.0200 (+0.55%) At close: 03:04PM CST

Hunan Er-Kang Pharmaceutical Co., Ltd

No. 167
Liuyang Economic Development Zone Kangping Road
Changsha 410331
China
86 731 8465 9108
https://www.hnerkang.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 1,497

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Qingrong Sun	GM & Non-Independent Director	N/A	N/A	1986
Ms. Zhao Xun	CFO & Non Independent Director	N/A	N/A	1988
Mr. Hai Ming Yang	Chief Engineer	N/A	N/A	1970
Ms. Xiangyang Shi	Deputy GM & Non Independent Director	N/A	N/A	1971
Mr. Licheng Zhang	Deputy General Manager	N/A	N/A	1979
Mr. Jishun Gu	Deputy GM & Board Secretary	N/A	N/A	1966

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's finished drugs primarily comprise sulbenicillin sodium for injection and compound liquorice tablets. Its conventional pharmaceutical excipients include pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose; and new pharmaceutical excipients comprise hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate and its series products. Hunan Er-Kang Pharmaceutical Co., Ltd was founded in 2003 and is based in Changsha, China.

Corporate Governance

Hunan Er-Kang Pharmaceutical Co., Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.